Delivery Order SPE2DB24D1034-SPE2DB25FWFN2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. The contract was awarded on September 25, 2025, with an ultimate completion date of September 26, 2025, and utilizes firm fixed price pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order....
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune and inflammatory conditions. This firm fixed price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $5,287.10 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside, competitively awarded contract features firm fixed price terms with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. As a major...
- The Defense Logistics Agency has awarded a delivery order valued at $13,635.57 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by October 16, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work from...
- The Defense Logistics Agency awarded a delivery order valued at $7,534.80 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price, non-set-aside contract was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls, a pharmaceutical product for treating autoimmune conditions. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. Performance will be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $19,051.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The award, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $4,926.76 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used for autoimmune disease treatment. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, carries firm fixed pricing and was competitively awarded with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.56 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competed delivery order under AmerisourceBergen's existing DLA contract vehicle. The place of performance is listed as the company's corporate office in...
- The Defense Logistics Agency awarded a $2,719.71 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of HUMIRA (CF) Pen 40 MG/0.4 MLS, a pharmaceutical product for treating autoimmune conditions. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- SPE2DB24D1034Indefinite Delivery Contract
- SPE2DB24D1034-SPE2DB25FWFN2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,587.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price, non-set-aside contract was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including delivery to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's selection reflects its demonstrated capability to meet federal procurement requirements through open competition and its established role as a critical vendor within the DLA's Medical Supply Chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/5/25 |